Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Joint destruction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists
The present invention discloses a novel compound and method for the treatment of inflammatory autoimmune diseases, for example, rheumatoid arthritis, using α-adrenergic antagonists and β-adrenergic agonists in combination. Treatment of animals, namely humans, with an α-adrenergic antagonist, preferably, phentolamine, and a β-adrenergic agonist, preferably terbutaline, in combination can significantly suppress the joint destruction and inflammation due to disease in these animals.
Owner:SUN HEALTH RES INST
Remedies for arthritis
InactiveUS20050175608A1Increase productionFacilitates dispersion and absorptionAntipyreticAnalgesicsGrowth retardantDiagnostic agent
The invention provides an agent for preventing or treating arthritis, a cartilage protecting agent, a joint destruction inhibitor and a synovial membrane growth inhibitor comprising an anti-FGF-8 neutralizing antibody as an active ingredient, as well as a diagnostic agent of arthritis comprising an anti-FGF-8 antibody as an active ingredient and a method for judging arthritis using the antibody.
Owner:KYOWA HAKKO KIRIN CO LTD
Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
ActiveUS20100286266A1Inhibit the inflammatory responseBiocideOrganic chemistryAnkylosing spondylitisTherapeutic effect
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as ‘BPSAAA compounds’), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and / or prevention, for example, of inflammation and / or joint destruction and / or bone loss; of disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.
Owner:PIMCO 2664
Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and / or joint destruction and / or bone loss; of disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).
Owner:PIMCO 2664
Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and / or joint destruction and / or bone loss; of disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.
Owner:PIMCO 2664
Aryl-phenyl-sulfonamide-phenylene compounds and their use
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and / or joint destruction and / or bone loss; of disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumor, etc.
Owner:PIMCO 2664
Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and / or joint destruction and / or bone loss; of disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).
Owner:PIMCO 2664
Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
Owner:PIMCO 2664
Methods for treating arthritic conditions in dogs
The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a hip or stifle of a canine which comprises administering to the canine a therapeutically effective amount of a bisphosphonate. The present invention also relates to method for eliciting a disease modifying effect on hip dysplasia or stifle instability, the pain associated with hip dysplasia or stifle instability, joint swelling, shallowing of the acetabulum, narrowing of the joint space, subchondral bone sclerosis, preventing osteophyte formation and preventing joint destruction in a canine which comprises administering to the canine a therapeutically effective amount of a bisphosphonate.
Owner:MERCK & CO INC +1
Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases.
Owner:MERCK & CO INC
A device and a method for analyzing joint destruction progress probability
InactiveCN109599175AUnderstand intuitiveMonitoring Treatment EffectsDesign optimisation/simulationSpecial data processing applicationsR languageTreatment effect
The invention discloses a device and a method for analyzing a joint destruction progress probability. The device comprises a parameter screening unit which is used for screening parameter variables for analyzing the joint destruction progress probability; a visual regression model generation unit which is used for constructing a column line graph by utilizing an R language according to the screened parameter variable data to obtain a visual regression model for analyzing the imaging joint damage progress risk probability of the rheumatoid arthritis patient; a data acquisition unit which is used for outputting each variable of the visual regression model obtained by the visual regression model generation unit through a graphical interface, providing data input and acquiring corresponding data input; And an analysis unit which is used for calculating the current input data by utilizing a visual regression model according to the obtained data of each variable to obtain a final analysis result, and the RA patient can intuitively analyze the joint damage progress risk probability in time and monitor the treatment effect of the disease.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Methods for treating arthritic conditions
InactiveUS20070004681A1Inhibition formationInhibit progressBiocidePhosphorous compound active ingredientsSubchondral boneBone epiphysis
The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a mammal which comprises administering to the mammal a therapeutically effective amount of an anti-resorptive compound. The present invention also relates to method for eliciting a disease modifying effect on subchondral bone sclerosis, preventing osteophyte formation or progression and preventing joint destruction in a mammal which comprises administering to the mammal a therapeutically effective amount of an anti-resorptive compound.
Owner:MERCK & CO INC
Methods For Treating Arthritic Conditions In Dogs
InactiveUS20080021001A1Inhibition formationAvoid destructionBiocideSkeletal disorderKnee JointInstability
The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a hip or stifle of a canine which comprises administering to the canine a therapeutically effective amount of a bisphosphonate. The present invention also relates to method for eliciting a disease modifying effect on hip dysplasia or stifle instability, the pain associated with hip dysplasia or stifle instability, joint swelling, shallowing of the acetabulum, narrowing of the joint space, subchondral bone sclerosis, preventing osteophyte formation and preventing joint destruction in a canine which comprises administering to the canine a therapeutically effective amount of a bisphosphonate.
Owner:MERIAL LTD
Test system and method for joint destruction effect of laser and surface airflow
The invention belongs to the laser application technology field, relates to a test system and method for the joint destruction effect of laser and the surface airflow and aims to solve disadvantages of high cost, the huge size and the narrow application scope existing in a test system in the prior art. The test system for the joint destruction effect of the laser and the surface airflow comprisesa target, a beam module, an airflow simulation module and a monitoring device, wherein the beam module comprises a laser device and a first total reflective mirror, the first total reflective mirror is arranged on an emission light path of the laser device, the airflow simulation module comprises a motor and a supporting assembly fixedly connected with a motor rotation shaft, the first total reflective mirror, the target and the monitoring device are fixed at an upper end of the supporting assembly, the first total reflective mirror is arranged in the middle, the target and the monitoring device are arranged at two sides of the first total reflective mirror, the light emitted by the laser device is reflected by the first total reflective mirror to irradiate onto the target, and a light signal on the surface of the target enters the monitoring device and is not blocked by the first total reflective mirror.
Owner:NORTHWEST INST OF NUCLEAR TECH
System for analyzing rheumatoid arthritis
ActiveCN110148465AMonitoring Treatment EffectsStay abreast of sabotage progressMedical automated diagnosisWater resource assessmentData acquisitionTherapeutic effect
The invention provides a system for analyzing rheumatoid arthritis (RA). The system according to the invention comprises a patient data acquisition module, a data input module and an analysis module,thereby understanding a joint destruction progress of an RA patient and monitoring the treatment effect of diseases in time. According to the system of the invention, a nuclear magnetic resonator utilizes a 3.0T whole-body scanning system realizes higher image resolution through increasing a signal-to-noise ratio by means of an eight-channel head coil. The average scanning time is only 24 minutes,thereby laying a solid basis for later clinical popularization.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Joint implant and prosthesis and method
Disclosed herein is a minimally invasive ball joint implant and prosthesis 10 for the treatment of arthritis, trauma, and other medical conditions leading to joint destruction and pain, as well as methods of use. In various cases, the prosthesis 10 does not require reaming into the intramedullary canal and does not require diaphyseal fit for any bones associated with the joint, thereby resulting in more rapid and complete recovery. In various cases, the prosthesis 10 incorporates an anchoring stem 38 specifically designed to be impacted into the bone and to facilitate bony ingrowth after implantation, thereby strengthening the implanted prosthesis 10 and preventing rotation thereof.
Owner:UNIVERSITY OF MISSOURI
Clinical condition evaluation new system for predicting one-year joint destruction progress of rheumatoid arthritis patient
PendingCN110136833AProgression of joint destruction is reduced or blockedDestruction progression is reduced or blockedHealth-index calculationIntensive treatmentLower risk
The invention discloses a clinical condition evaluation new system for predicting a one-year joint destruction progress of a rheumatoid arthritis patient. According to the invention, a new index whichcan be used for predicting the one-year joint destruction progress of the rheumatoid arthritis patient is researched, namely a limb muscle index (ASMI), and the clinical condition evaluation new system for predicting the one-year joint destruction progress of the rheumatoid arthritis patient is established based on the limb muscle index. The system can accurately screen the high-risk patient, themiddle-risk patient and the low-risk patient in the one-year joint destruction progress earlier than prior art for nine months to one year, and different treatment plans are utilized for the high-risk patient, the middle-risk patient and the low-risk patient, thereby realizing intensive treatment of the high-risk patient and the middle-risk patient earlier for nine months to one year, guiding clinical medicine taking for more effectively reducing or blocking the joint destruction progress of the rheumatoid arthritis patient, preventing disability, and realizing important meaning and high value in treatment controlling and monitoring of rheumatoid arthritis.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and / or joint destruction and / or bone loss; disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and / or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
Owner:PIMCO 2664
Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists
The present invention discloses a novel compound and method for the treatment of inflammatory autoimmune diseases, for example, rheumatoid arthritis, using α-adrenergic antagonists and β-adrenergic agonists in combination. Treatment of animals, namely humans, with an α-adrenergic antagonist, preferably, phentolamine, and a β-adrenergic agonist, preferably terbutaline, in combination can significantly suppress the joint destruction and inflammation due to disease in these animals.
Owner:SUN HEALTH RES INST
Gene sensitive to bone/joint disease and use thereof
InactiveUS20100239501A1Easy to measureHigh expressionCompound screeningNervous disorderSacroiliac jointJoint destruction
The present invention provides a suppressing agent for inflammatory cytokine expression in joints and / or joint destruction (e.g., articular cartilage destruction) and / or pain in a bone / joint disease, comprising a substance that suppresses the expression or activity of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:2, a screening method for a substance that regulates inflammatory cytokine expression in joints and / or joint destruction (e.g., articular cartilage destruction) and / or pain in a bone / joint disease, comprising using the protein or a partial peptide thereof, and a diagnostic method for genetic susceptibility to a bone / joint disease, comprising detecting a polymorph in the base shown by base number 24007 in the partial base sequence of the human EDG2 gene shown by SEQ ID NO:3.
Owner:RIKEN +1
A phase shifter with a built-in transmission rod
ActiveCN105070979BReduce in quantityReduce hidden dangers of intermodulationWaveguide type devicesDielectricElectrical conductor
The invention discloses a phase shifter with a built-in transmission rod. The PCB is sandwiched between two dielectric sheets, and the three buckles of each dielectric sheet are inserted into the corresponding round holes of the built-in transmission rod through slight deformation. On the second rectangular groove, the cavity of the phase shifter is made of aluminum alloy extruded profile structure. The first limit protrusion structure in the cavity of the phase shifter is used to limit and guide the built-in transmission rod, optimizing the downtilt angle Accuracy, reducing the number of parts, saving assembly time, and reducing hidden dangers of intermodulation. The insulating layer of the coaxial cable passes through the bottom round hole of the semicircular groove, the inner conductor is lapped on the PCB pad for welding, and a round hole for welding process is opened on the wall of the phase shifter cavity directly above the PCB pad. For the welding pad, the outer conductor of the coaxial cable is directly welded on the semicircular groove outside the profile, which reduces the number of parts, saves assembly time, reduces the risk of solder joint damage, and reduces the hidden danger of intermodulation.
Owner:WUHAN HONGXIN TELECOMM TECH CO LTD
Application of polygonum cuspidatum, polydatin and emodin in treatment of rheumatoid arthritis
ActiveCN110123883AInhibition of unanchored growthOrganic active ingredientsAntipyreticJoint arthralgiaPOLYGONUM CUSPIDATUM
The invention relates to an application of polygonum cuspidatum, polydatin and emodin in treatment of rheumatoid arthritis. In particular, the invention discloses polygonum cuspidatum, polydatin and emodin which can alleviate symptoms related to rheumatoid arthritis, such as arthralgia, swelling, morning stiffness and / or joint destruction.
Owner:DONGFANG HOSPITAL BEIJING UNIV OF CHINESE MEDICINE
Measuring instrument for artificial hip joint pressure
InactiveCN111214316AImprove the accuracy of prosthesis installationGood curative effectJoint implantsAcetabular cupsMeasuring instrumentMetastatic bone tumor
The invention relates to the technical field of medical surgical auxiliary equipment, and discloses a measuring instrument for artificial hip joint pressure. The measuring instrument includes an acetabular lining trial mold, the acetabular lining trial mold is composed of an acetabular lining shell, pressure sensors and a bluetooth signal transmitter, and the acetabular lining trial mold can be indata connection with computer equipment. The measuring instrument for the artificial hip joint pressure can improve the installation accuracy of artificial total hip replacement surgery and obtain amore ideal stress distribution, thereby improving the therapeutic effect of the artificial total hip replacement surgery; and the measuring instrument can be used for treatment of femoral neck fracture, femoral head necrosis, hip osteoarthritis, hip ankylosis, hip rheumatoid arthritis, acetabular dysplasia, hip primary / metastatic bone tumors, and other severe hip bone lesions with joint destruction.
Owner:南京冬尚生物科技有限公司
Application of B cell vaccine in preparation of drugs for treating rheumatoid arthritis
ActiveCN110585428AReduce dosageReduce dosing frequencyCell dissociation methodsAntipyreticDiseaseSide effect
The present invention discloses an application of a B cell vaccine in preparation of drugs for treating rheumatoid arthritis and the B cell vaccine having the application. Compared with drug treatment, the B cell vaccine has the following advantages of being smaller in dosage, lower in administration frequency, longer in maintenance period, and simple and convenient in subcutaneous injection, cantreat diseases through autoimmune regulation functions, can effectively control the diseases, reduces bone erosion and joint destruction, and is free of immune tolerance problems in autotransfusion and small in side effects.
Owner:PEOPLES HOSPITAL PEKING UNIV
Remedies for arthritis
InactiveUS7708999B2Increase productionFacilitates dispersion and absorptionAntipyreticAnalgesicsDiagnostic agentNeutralizing antibody
Owner:KYOWA HAKKO KIRIN CO LTD
Compositions and methods for treating metabolic disorders
PendingUS20210346328A1Rescued structureModify joint destructionSkeletal disorderKetone active ingredientsSubchondral boneCartilage degeneration
Provided herein are methods of treating, delaying progression of, or reducing the severity of metabolic disorders characterized with increased COX-2 expression and / or PGE2 expression and / or EP4 expression in bone related cells through administration of an agent configured to inhibit and / or diminish COX-2 expression, and / or PGE2 expression, and / or EP4 expression in bone related cells. In some embodiments, such administration results in one or more of the following: inhibited or reduced COX-2 expression; inhibited or reduced PGE2 expression; inhibited or reduced EP4 expression; inhibited or reduced aberrant subchondral bone remodeling and / or innervation; inhibited or reduced cartilage degeneration; and inhibited or reduced joint destruction.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Compositions and Methods for Preventing Joint Destruction in Osteoarthritis
InactiveUS20130035357A1Lower Level RequirementsInhibiting degradation of collagenBiocideAntipyreticJoint destructionBexarotene
The present invention is methods for inhibiting collagen destruction in joints of osteoarthritis patients. The methods are based on use of rexinoid compounds, in particular bexarotene, and their activity to inhibit synthesis of matrix metalloproteinases (MMPs) in affected tissue.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Genetic markers for bone mass
InactiveUS20050176006A1Microbiological testing/measurementAntiendomysial antibodiesNeutralising antibody
The invention provides an agent for preventing or treating arthritis, a cartilage protecting agent, a joint destruction inhibitor and a synovial membrane growth inhibitor comprising an anti-FGF-8 neutralizing antibody as an active ingredient, as well as a diagnostic agent of arthritis comprising an anti-FGF-8 antibody as an active ingredient and a method for judging arthritis using the antibody.
Owner:THE UNIV COURT OF THE UNIV OF ABERDEEN REGENT WALK
Treatment of Rheumatoid Arthritis Using Noble Gas Mixtures
The invention disclosed provides means of inhibiting, ameliorating, and / or treatment of rheumatoid arthritis through the use of Noble gas containing mixtures. In one embodiment, the invention provides means of reducing inflammation and immune associated pathology through administration of Noble gas mixtures. In one specific embodiment, Xenon gas is administered to a patient in need at concentrations and frequencies sufficient to inhibit inflammatory and autoimmune processes. In another embodiment Noble gas mixtures are administered to reduce pain and provide symptomatic relieve to a patient suffering from rheumatoid arthritis. In another embodiment the use of Noble gas containing mixtures is disclosed as a means of reducing joint destruction through inhibition of matrix metalloprotease production and activity.
Owner:NOBILIS THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com